Articles
Model-Projected Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) in Patients With Transfusion-Dependent Beta-Thalassemia in Canada
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Udeze C1, Gargano M1, Kaindl L2, Kane S2, Zhou A2, Jain S1, Lopez A1 | 1Vertex Pharmaceuticals Incorporated, Boston, MA, USA, 2Eversana, Burlington, ON, Canada
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Rare & Orphan Diseases
Systematic Literature Review of Cost-Effectiveness Evaluations of Freestyle Libre Continuous Glucose Monitoring Systems
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- De Pouvourville G1, Timmons J2, Levrat Guillen F2, Zara A3, Poon Y2 | 1ESSEC, Paris, Ile de France, France, 2Abbott Diabetes Care, Alameda, CA, USA, 3Eversana, Burlington, ON, Canada
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Diabetes/Endocrine/Metabolic Disorders
Systematic Literature Review (SLR) of Randomized Controlled Trials (RCTs) of Treatments for First-Line (1L) Gastric Cancer/Gastroesophageal Junction Adenocarcinoma (GC/GEJ) in Adult Patients
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Smyth E1, Kangappaden T2, Portuhay S2, Debnath A2, Craigie S2, Coaquira Castro J3, Priedane E4, Zhan L3 | 1Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK, 2EVERSANA, Burlington, ON, Canada, 3BeiGene USA, Inc., Emeryville, CA, USA, 4BeiGene UK, Ltd., London, LON, UK
- Publication Date:
- Literature Review & Synthesis
- Condition:
- Oncology
Patient-Centric Approaches in Rare Disorder Research: An In-Depth Systematic Review
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Verma A1, Chinchapattanam D1, Barathe P1, Krishna A1, Pruthi J1, Rai MK2, Prasanna R1 | 1EVERSANA, Mumbai, MH, India, 2EVERSANA, Singapore, Singapore
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Rare & Orphan Diseases
NICE vs SMC: Reimbursement Differences for Non-Oncology Orphan Drugs
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Dey R, EVERSANA, Pune, India
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Rare & Orphan Diseases
Indirect Treatment Comparison of Iptacopan Versus Eculizumab and Ravulizumab for Patients With Paroxysmal Nocturnal Hemoglobinuria Naive to C5 Inhibitors
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Peffault de Latour R1, Scheinberg P2, Spin P3, Balp MM4, Pannagl K5, Wiyani A6, Somenzi O4, Snellman J4, Wang P3, Steenkamp J3, Kulasekararaj A7 1French Référence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France, 2Hospital A Beneficência Portuguesa, São Paulo, Brazil, 3EVERSANA, Burlington, ON, Canada, 4Novartis Pharma AG, Basel, BS, Switzerland, 5Novartis Pharmaceuticals UK Ltd, London, LON, UK, 6Novartis Pharmaceuticals UK Ltd, London, UK, 7King’s College Hospital NHS, London, UK
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Rare & Orphan Diseases
Health State Utility Values for Patients With Paroxysmal Nocturnal Hemoglobinuria Using EQ-5D-5L
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Wang P1, Steenkamp J1, Balp MM2, Wiyani A3, Pannagl K4 1EVERSANA, Burlington, ON, Canada, 2Novartis Pharma AG, Basel, BS, Switzerland, 3Novartis Pharmaceuticals UK Ltd, London, UK, 4Novartis Pharmaceuticals UK Ltd, London, LON, UK
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Rare & Orphan Diseases
The Economic and Environmental Burden of Hydrophilic and Hydrophobic IOLs in the UK
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- O'Boyle D1, Rychlik J2, Wright G2 1Alcon Vision LLC, Sligo, SO, Ireland, 2EVERSANA, Burlington, ON, Canada
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Eye
Systematic Literature Review (SLR) of Disease Burden Related to First-Line (1L) Unresectable, Locally Advanced, or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
- Journal/Conference:
- 2024-11, ISPOR Europe 2024, Barcelona, Spain
- Author(s):
- Smyth E1, Sibiga A2, Nehdi AN2, Krishna A3, Kim K2, Coaquira Castro J4, Priedane E5, Zhan L4 1Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK, 2EVERSANA, Burlington, ON, Canada, 3EVERSANA India Private Limited, Mumbai, MH, India, 4BeiGene USA, Inc., Emeryville, CA, USA, 5BeiGene UK, Ltd., London, LON, UK
- Publication Date:
- Value in Health, Volume 27, Issue 12, S2 (December 2024)
- Condition:
- Cancer
Coding and Reimbursement Assessment for Potential Acquisition
Posted on November 4, 202411/4/24